Internal Medicine, Infectious Disease · Palm Springs, CA
NPI
1538102207
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1695 N Sunrise Way
Palm Springs, CA, 92262
Phone (760) 323-2118
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
257 services
Medicare patients, 2024
48
Average age 71
Drug cost, 2024
$6.6M
1,940 prescriptions
Company payments, 2025
$432
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shubha J Kerkar was code 99233 (hospital e&m - subsequent), 203 times for 40 patients. In total Shubha J Kerkar billed 257 services in 3 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-11-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 203 | 40 | $94.51 | $19K |
| 99223 Hospital E&M - Initial | Facility | 41 | 40 | $138.04 | $5,660 |
| 99232 Hospital E&M - Subsequent | Facility | 13 | 11 | $62.84 | $817 |
By year: 2022 $36K for 363 services; 2023 $26K for 260 services; 2024 $26K for 257 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shubha J Kerkar prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 586 prescriptions and refills. In total Shubha J Kerkar wrote 1,940 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 586 | 630 | 73 | $2.5M |
| Juluca Dolutegravir/Rilpivirine | 199 | 220 | 25 | $771K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 170 | 200 | 21 | $746K |
| Tivicay Dolutegravir Sodium | 163 | 173 | 19 | $496K |
| Prezcobix Darunavir/Cobicistat | 130 | 130 | 14 | $310K |
| Descovy Emtricitabine/Tenofov Alafenam | 106 | 116 | 15 | $254K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 67 | 71 | Under 11 | $291K |
| Cabenuva Cabotegravir/Rilpivirine | 48 | 89 | 11 | $304K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 45 | 45 | Under 11 | $167K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 36 | 46 | Under 11 | $242 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 29 | 37 | Under 11 | $164K |
| Vemlidy Tenofovir Alafenamide | 28 | 36 | Under 11 | $51K |
| Pifeltro Doravirine | 23 | 23 | Under 11 | $47K |
| Fluconazole Generic | 21 | 34 | Under 11 | $2,246 |
| Doxycycline Hyclate Generic | 20 | 20 | Under 11 | $231 |
Brand drugs: 1,682 claims; generic drugs: 258 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shubha J Kerkar $432 ($432 in general payments such as food, travel and fees) from 3 companies. The largest payer was Abbvie Inc. with $390.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.